STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more

Cigna will stop covering GLP-1 weight loss drugs like Wegovy and Zepbound in its employee health plan starting July 1, directing users to cash-pay options. A study suggests long-term use of GLP-1 drugs could reduce knee replacement risk by up to 5% over eight years. Prices for these drugs are declining in 2026 with new oral versions.